Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 233-248

  Perrine, Susan P ^a   Pace, Betty S ^b   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Beta thalassemia; Fetal hemoglobin; Genetic modifiers; Sickle cell disease; Stress signaling

Indexed keywords

ERYTHROID KRUPPEL LIKE FACTOR; GLOBIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HISTONE DEACETYLASE 3; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 1; PROTEIN; PROTEIN BCL 11A; UNCLASSIFIED DRUG; BUTYRIC ACID DERIVATIVE; HEMOGLOBIN ALPHA CHAIN;

BETA THALASSEMIA; CELL SURVIVAL; DEMETHYLATION; ERYTHROID CELL; GENE ACTIVATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; GLOBIN GENE; HEMOGLOBINOPATHY; HUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; RNA TRANSLATION; ANEMIA, SICKLE CELL; ANIMAL; BETA-THALASSEMIA; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; HEMOGLOBINOPATHIES; TRANSCRIPTION INITIATION;

ALPHA-GLOBINS; ANEMIA, SICKLE CELL; ANIMALS; BETA-THALASSEMIA; BUTYRATES; FETAL HEMOGLOBIN; HEMOGLOBINOPATHIES; HUMANS; MODELS, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84896880810     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.009     Document Type: Review

References (79)

1. Steinberg M.H., Rodgers G.P. Pharmacologic modulation of fetal hemoglobin. Medicine 2001, 80:328-344.
2. Perrine S.P. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann 2008, 37:339-346.
3. Gallo E., Massaro P., Miniero R., et al. The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia. Br J Haematol 1979, 41:211-221.
4. Schrier S.L. Pathobiology of thalassemic erythrocytes. Curr Opin Hematol 1997, 4:75-78.
5. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol 2005, 33:259-271.
6. Centis F., Tabellini L., Lucarelli G., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000, 96:3624-3629.
7. Mathias L.A., Fisher T.C., Zeng L., et al. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 2000, 28:1343-1353.
8. Pootrakul P., Sirankapracha P., Hemsorach S., et al. Acorrelation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000, 96:2606-2612.
9. Collins A.F., Pearson H.A., Giardina P., et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995, 85:43-49.
10. Perrine S.P., Ginder G.D., Faller D.V., et al. Ashort-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. NEngl J Med 1993, 328:81-86.
11. Cao H., Stamatoyannopoulos G., Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 2004, 103:701-709.
12. Cappellini D., Graziadei M.G., Ciceri L., et al. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol Dis 2000, 26:105-111.
13. Hajjar F.M., Pearson H.A. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. JPediatr 1994, 125:490-492.
14. Singer S.T., Kuypers F.A., Olivieri N.F., et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol 2005, 131:378-388.
15. Atweh G.F., Sutton M., Nassif I., et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999, 93:790-797.
16. Ley T.J., DeSimone J., Anagnou N.P., et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. NEngl J Med 1982, 307:1469-1475.
17. Saunthararajah Y., Hillery C.A., Lavelle D., et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003, 102:3865-3870.
18. Bourantas K., Economou G., Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Eur J Haematol 1997, 58:22-25.
19. Galanello R., Barella S., Turco M.P., et al. Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients. Blood 1994, 83:561-565.
20. Thein S.L., Menzel S., Lathrop M., et al. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet 2009, 18:R216-R223.
21. Sankaran V.G., Xu J., Byron R., et al. Afunctional element necessary for fetal hemoglobin silencing. NEngl J Med 2011, 365(9):807-814.
22. Wang W.C., Ware R.E., Miller S.T., et al. Hydroxycarbamide in very young children with sickle- cell anaemia: a multicentre, randomized, controlled trial (BABY HUG). Lancet 2011, 377:1663-1672.
23. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. NEngl J Med 1995, 332(2):1317-1322.
24. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. NEngl J Med 1994, 330:1639-1644.
25. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003, 289:1645-1651.
26. Steinberg M.H., McCarthy W.F., Castro O., et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010, 85:403-408.
27. Perrine S.P., Castaneda S.A., Chui D.H., et al. Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci 2010, 1202:158-164.
28. Fucharoen S., Siritanaratkul N., Winichagoon P., et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood 1996, 87:887-892.
29. Nuinoon M., Makarasara W., Mushiroda T., et al. Agenome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum Genet 2010, 127:303-314.
30. Jiang J., Best S., Menzel S., et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006, 108:1077-1083.
31. Garner C., Mitchell J., Hatzis T., et al. Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am J Hum Genet 1998, 62:1468-1474.
32. Labie D., Pagnier J., Lapoumeroulie C., et al. Common haplotype dependency ofhigh G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci USA 1985, 82:2111-2114.
33. Uda M., Galanello R., Sanna S., et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008, 105:1620-1625.
34. Bradner J.E., Mak R., Tanguturi S.K., et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 2010, 107(28):12617-12622.
35. Thein S.L., Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009, 145:455-467.
36. Sedgewick A.E., Timofeev N., Sebastiani P., et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis 2008, 41(3):255-258.
37. Lettre G., Sankaran V.G., Bezerra M.A., et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008, 105(33):11869-11874.
38. Guy L.G., Mei Q., Perkins A.C., et al. Erythroid Kruppel-like factor is essential for beta-globin gene expression even in absence of gene competition, but is not sufficient to induce the switch from gamma-globin to beta-globin gene expression. Blood 1998, 91(7):2259-2263.
39. Bianchi E., Zini R., Salati S., et al. c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood 2010, 116(22):e99-e110.
40. Bauer D.E., Kamran S.C., Orkin S.H. Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood 2012, 120(15):2945-2953.
41. Borg J., Papadopoulos P., Georgitsi M., et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010, 42(9):801-805.
42. Zhou D., Liu K., Sun C.W., et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010, 42(9):742-744.
43. Kulozik A.E., Bellan-Koch A., Bail S., et al. Thalassemia intermedia: moderate reduction of beta globin gene transcriptional activity by a novel mutation of the proximal CACCC promoter element. Blood 1991, 77:2054-2058.
44. Orkin S.H., Antonarakis S.E., Kazazian H.H. Base substitution at position -88 in a beta- thalassemic globin gene. Further evidence for the role of distal promoter element ACACCC. JBiol Chem 1984, 259:8679-8681.
45. Orkin S.H., Kazazian H.H., Antonarakis S.E., et al. Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. Nature 1982, 296:627-631.
46. Lin H.J., Han C.Y., Nienhuis A.W. Functional profile of the human fetal gamma-globin gene upstream promoter region. Am J Hum Genet 1992, 51:363-370.
47. Ulrich M.J., Ley T.J. Function of normal and mutated gamma-globin gene promoters in electroporated K562 erythroleukemia cells. Blood 1990, 75:990-999.
48. Miller I.J., Bieker J.J. Anovel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol 1993, 13:2776-2786.
49. Sankaran V.G., Xu J., Ragoczy T., et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009, 60:1093-1097.
50. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
51. Xu J., Sankaran V.G., Ni M., et al. Transcriptional silencing of gamma-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 2010, 24:783-798.
52. Yi Z., Cohen-Barak O., Hagiwara N., et al. Sox6 directly silences epsilon globin expression in definitive erythropoiesis. PLoS Genet 2006, 2:e14.
53. Song C.Z., Keller K., Murata K., et al. Functional interaction between coactivators CBP/p300, PCAF, and transcription factor FKLF2. JBiol Chem 2002, 277:7029-7036.
54. Zhang P., Basu P., Redmond L.C., et al. Afunctional screen for Kruppel-like factors that regulate the human gamma-globin gene through the CACCC promoter element. Blood Cells Mol Dis 2005, 35:227-235.
55. Gardiner M.R., Gongora M.M., Grimmond S.M., et al. Aglobal role for zebrafish klf4 in embryonic erythropoiesis. Mech Dev 2007, 124:762-774.
56. Kalra I., Alam M., Choudhary P., et al. KLF4 activates HBG gene expression in primary erythroid cells. Br J Haematol 2011, 154:248-259.
57. Perrine S.P., Greene M.F., Cohen R.A., et al. Delayed fetal globin switching in infants of diabetic mothers is associated with specific DNA hypomethylation. FEBS Lett 1988, 228:139-143.
58. DeSimone J., Heller P., Hall L., et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982, 79(14):4428-4431.
59. Cui S., Kolodziej K.E., Obara N., et al. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic beta-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol 2011, 31(16):3298-3311.
60. Mankidy R., Faller D.V., Mabaera R., et al. Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood 2006, 108:3179-3186.
61. Kutlar A., Ataga K., Reid M., et al. Aphase I/II trial of HQK-1001, a fetal globin gene inducer, in sickle cell disease. Am J Hematol 2012, 87(11):1017-1021. 10.1002/ajh.23306.
62. Fuchareon S., Inati A., Siritanaraku N., et al. Arandomized phase I/II trial of HQK-1001, an oral foetal globin gene inducer, in beta thalassemia intermedia and HbE beta thalassemia. Br J Haematol 2013, 161(4):587-593. 10.1111/bjh.12304.
63. Bohacek R., Boosalis M.S., McMartin C., et al. Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des 2006, 67:318-328.
64. Perrine S.P., Mankidy R., Boosalis M.S., et al. Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol 2009, 82:466-476.
65. Chen Z., Luo H.Y., Steinberg M.H., et al. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 2009, 42:144-149.
66. Sheehan V.A., Luo Z., Flanagan J.M., et al. Genetic modifiers of sickle cell anemia in the Baby HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol 2013, [Epub ahead of print]. 10.1002/ajh.23457.
67. Lavelle D., Vaikus K., Ling Y., et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 2012, 119:1240-1247. 10.1182/blood-2011-08-371690.
68. Perrine S.P., Welch W.C., Keefer J., et al. Evaluation of safety and pharmacokinetics of sodium 2, 2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single- and repeat-dose studies in healthy volunteers. JClin Pharmacol 2011, 51:1186-1194. 10.1177/0091270010379810.
69. Sangerman J.I., Boosalis M.S., Shen L., et al. Identification of new and diverse inducers of fetal hemoglobin with high throughput screening (HTS). Blood 2010, 116:4277. [abstract].
70. Perrine S., Faller D.V., Shen L., et al. HQK-1001 has additive HbF-inducing activity in combination with hydroxyurea and decitabine. Blood 2009, 114:977. [abstract].
71. Shi L., Cui S., Engel J.D., et al. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med 2013, 19:291-294.
72. Sangerman J., Lee M.S., Yao X., et al. Mechanisms for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma globin activation by CREB1 and ATF-2. Blood 2006, 108(10):3590-3599.
73. Hahn C.K., Lowrey C.H. Eukaryotic initiation factor 2alpha phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism. Blood 2013, 122(4):477-485. 10.1182/blood-2013-03-491043.
74. Chen J.J., Perrine S. Stressing HbF synthesis: role of translation?. Blood 2013, 122:467-468. 10.1182/blood-2013-06-506139.
75. Castaneda S., Boosalis M.S., Emery D., et al. Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis 2005, 35:217-226.
76. Boosalis M.S., Bandyopadhyay R., Bresnick E.H., et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 2001, 97:3259-3267.
77. Pace B.S., White G.L., Dover G.J., et al. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis invivo. Blood 2002, 100:4640-4648.
78. Ikuta T., Kan Y.W., Swerdlow P.S., et al. Alterations in protein-DNA interactions in the gamma globin gene promoter in response to butyrate therapy. Blood 1998, 92:2924-2933.
79. Sheehan V.A., Howard T.A., Sabo A., et al. Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia. Blood 2012, 120. Abstract 241.